Menarini Group Presents Elacestrant (ORSERDU) Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2025 San Antonio Breast Cancer Symposium
In addition, the expansive elacestrant clinical development program updates reinforce its potential as…
Novartis data underscore pioneering scientific innovation in Hematology and Oncology at ASH and SABCS
Positive results from ianalumab pivotal Phase III trial in ITP patients previously…
